ArticlePharmacological research2019
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
Open access · greenAbstract read
In one paragraph
Article in Pharmacological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Cannabinoid CBBritish journal of pharmacology · 2026Article
- Glucocorticoid-endocannabinoid crosstalk in the ventrolateral periaqueductal gray (vlPAG) promotes pain resolution.bioRxiv : the preprint server for biology · 2026Article
- Enzyme-Integrated Hydrogels for Advanced Biological Applications.Polymer science & technology (Washington, D.C.) · 2026Review
- Evaluation of the Cytotoxic Activity of Nanostructured Lipid Carrier Systems for Fatty Acid Amides and Silk Fibroins in Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2025Article
- Article
- Evaluation and application analysis of animal models of PIPNP based on data mining.Open life sciences · 2025Review
- Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment.Life (Basel, Switzerland) · 2024Review
- Review
- Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats.Frontiers in pharmacology · 2024Article
- Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.International journal of molecular sciences · 2023Article
- Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway.Cell death & disease · 2023Article
- N-linoleyltyrosine resisted the growth of non-small cell lung cancer cells via the regulation of CBFrontiers in pharmacology · 2023Article
- Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Review
- Fatty acid amide hydrolase activity in the dorsal periaqueductal gray attenuates neuropathic pain and associated dysautonomia.American journal of physiology. Regulatory, integrative and comparative physiology · 2022Article
- The Peripheral Cannabinoid Receptor Type 1 (CBMolecules (Basel, Switzerland) · 2021Review
- Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy.International journal of molecular sciences · 2021Review
- Review of the Role of the Brain in Chemotherapy-Induced Peripheral Neuropathy.Frontiers in molecular biosciences · 2021Review
- Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.The Journal of pharmacy and pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Richard A SlivickiProgram in Neuroscience, Indiana University, Bloomington, IN, United States; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States.
Zhili XuDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States.
Sonali S MaliDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States.
Andrea G HohmannProgram in Neuroscience, Indiana University, Bloomington, IN, United States; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, United States. Electronic address: hohmanna@indiana.edu.
Indiana University Bloomington · US
Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MINTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITYT32DA024628 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2008 to 2026
$3.1MCB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2019 to 2023
$2.6MRole of CB2 in Analgesic MechanismsR01DA041229 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2016 to 2020
$1.8MNOS1AP as a novel target for treating pathological painR01CA200417 · NCI · TRUSTEES OF INDIANA UNIVERSITY · PI COURTNEY, MICHAEL, HOHMANN, ANDREA GRACE · 2016 to 2020
$1.4MA Novel Mechanism for Decreasing Opioid RewardR21DA042584 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, REBEC, GEORGE VINCENT · 2016 to 2017
$392kNCI NIH HHS R01 CA200417NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA041229NIDA NIH HHS R01 DA047858NIDA NIH HHS R21 DA042584NIDA NIH HHS T32 DA024628
Abstract
Activation of cannabinoid CB
Indexed as
AmidohydrolasesAnalgesicsAnimalsAntineoplastic AgentsBenzamidesBenzoxazinesBrainCannabinoidsCarbamatesCell Line, TumorCell SurvivalDrug SynergismDrug ToleranceFatty Acid Amide HydrolasesHEK293 CellsHumans(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneAmidohydrolasesAnalgesicsAntineoplastic AgentsBenzamidesBenzoxazinesCannabinoidsCarbamatescyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterFatty Acid Amide HydrolasesMorpholinesNaphthalenesPaclitaxelURB9374T1CannabinoidChemotherapy-induced neuropathic painFatty-acid amide hydrolaseHeyA8PaclitaxelPaclitaxel (PubChem CID: 436314)Rimonabant (PubChem CID: 104850)URB597 (PubChem CID: 1383884)URB937 (PubChem CID: 53394762)WIN55,212-2 (PubChem CID: 5311501)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.